Published in Ann Transl Med on December 01, 2016
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature (2014) 3.10
Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity (2015) 2.12
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun (2009) 1.71
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine (2008) 1.32
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood (2015) 1.18
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med (2015) 1.10
Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 1.09
Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol (2016) 1.04
Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw (2013) 1.03
The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol (2011) 0.95
Interleukin-33 in health and disease. Nat Rev Immunol (2016) 0.92
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun (2015) 0.90
The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response. EBioMedicine (2016) 0.88
Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med (2013) 0.87
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol (2014) 0.87
IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy (2015) 0.87
Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model. Am J Pathol (2011) 0.87
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood (2016) 0.87
Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol (2012) 0.83
Generation and characterization of rat anti-mouse ST2L monoclonal antibodies. Hybridoma (Larchmt) (2011) 0.81
Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections. Trends Pharmacol Sci (2016) 0.78
Prognostic biomarkers in acute coronary syndrome. Ann Transl Med (2016) 0.78
Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags". MAbs (2015) 0.78